University of Leiden
The Leiden/Amsterdam Center for Drug Research (LACDR) is one of the leading institutes in identifying novel drug targets for cancer, vascular diseases and neurological disorders and designing novel drug leads. Within the division of Toxicology (LACDR) a main theme is on molecular mechanisms of cancer development and progression with a focus on metastasis programs mediated by integrin- and kinase-mediated signalling. Functional genomics and live high content imaging approaches are used to identify candidate drug targets to combat cancer metastasis. Genetic breast cancer development and progression models in combination with cutting edge intravital imaging technologies are available to evaluate the invasive and metastatic properties of candidate metastasis genes.
Partner UL is involved in:
1) establishing novel metastasis modulating genes based on siRNA functional genomics approaches and live cell imaging
2) establishing breast cancer metastasis model for in vivo intravital and bioluminescence imaging quantitative analysis and tumor cell dissemination
3) establish the relevance of candidate metastasis genes using mouse mammary epithelial cell transplantation models for spontaneous breast tumor formation/spread caused by oncogenic transformation.
List of persons involved in MetaFight
- Prof. Bob van de Water - Professor of Drug Safety Sciences, Head of division Toxicology - MetaFight Principal Investigator
- Dr. Marjo de Graauw
- Dr. Sandra Zovko
- Drs. Sylvia le Devedec
- Drs. Wies van Roosmalen
- Ing. Chantal Pont
- Ing. Reshma Lalai